BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JNJ-88998377 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JNJ-88998377\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06470438-11224@assetmemo.bio
DTSTAMP:20261121T005740Z
DTSTART;VALUE=DATE:20271029
DTEND;VALUE=DATE:20271030
SUMMARY:JNJ-88998377: Phase 1 readout est. (NCT06470438)
DESCRIPTION:JNJ-88998377\, phase 1\, B-Cell Non-Hodgkin Lymphoma.\nStudy: A
  Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lympho
 ma\nEstimated primary completion: 29 October 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/jnj-88998377#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06470438
URL:https://assetmemo.bio/drug/jnj-88998377#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
